By Financial News Desk October 23, 2026 Dr. Reddy’s Laboratories, one of India’s premier pharmaceutical giants, is navigating a complex transition in its high-stakes portfolio of generic semaglutide injections. Following significant supply-chain disruptions and the discovery of quality-control issues in its flagship "Obeda" brand, the company has introduced two new iterations—Obeda Pro and Obeda Plus—to […]
Headline
Tag: semaglutide
Back To Top